Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:BIVV
CUSIPN/A
Phone+1-781-6634400
Debt
Debt-to-Equity RatioN/A
Current Ratio2.00
Quick Ratio1.89
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E Ratio27.48
P/E Growth1.96
Sales & Book Value
Annual Sales$1.17 billion
Price / Sales9.72
Cash Flow$2.8754 per share
Price / Cash36.51
Book Value$8.29 per share
Price / Book12.66
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$355.60 million
Net Margins30.43%
Return on Equity40.99%
Return on Assets22.79%
Miscellaneous
Employees460
Outstanding Shares108,220,000
Bioverativ (NASDAQ:BIVV) Frequently Asked Questions
What is Bioverativ's stock symbol?
Bioverativ trades on the NASDAQ under the ticker symbol "BIVV."
How were Bioverativ's earnings last quarter?
Bioverativ Inc (NASDAQ:BIVV) posted its earnings results on Thursday, October, 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the Zacks' consensus estimate of $0.55 by $0.25. The biotechnology company had revenue of $291.60 million for the quarter, compared to the consensus estimate of $285.45 million. Bioverativ had a return on equity of 40.99% and a net margin of 30.43%. The company's quarterly revenue was up 27.2% compared to the same quarter last year. View Bioverativ's Earnings History.
What price target have analysts set for BIVV?
12 brokerages have issued 12 month price objectives for Bioverativ's stock. Their predictions range from $47.00 to $80.00. On average, they expect Bioverativ's share price to reach $65.00 in the next year. View Analyst Ratings for Bioverativ.
What are Wall Street analysts saying about Bioverativ stock?
Here are some recent quotes from research analysts about Bioverativ stock:
- 1. William Blair analysts commented, "We are dropping coverage of Bioverativ , Inc. following the completion of its acquisition by Sanofi (SNY $39.90). Our final rating on Bioverativ was Market Perform." (3/8/2018)
- 2. According to Zacks Investment Research, "Bioverativ Inc. is a biotechnology company. It focuses on the discovery, research, development, and commercialization of innovative therapies for the treatment of hemophilia and other blood disorders. Bioverativ Inc. is based in Waltham, United States. " (1/8/2018)
- 3. Cowen Inc analysts commented, "Bioverativ reported Q2 revenue of $289MM (+38% Y/Y) versus consensus of." (8/4/2017)
Who are Bioverativ's key executives?
Bioverativ's management team includes the folowing people:
- Brian S. Posner, Independent Chairman of the Board (Age 55)
- John G. Cox, Chief Executive Officer, Director (Age 54)
- John T. Greene, Chief Financial Officer, Executive Vice President, Treasurer (Age 51)
- Rogerio Vivaldi Coelho M.D., Executive Vice President, Chief Global Therapeutic Operations Officer (Age 53)
- Lucia Celona, Executive Vice President, Chief Human Resources and Corporate Communications Officer (Age 51)
- Richard Brudnick, Executive Vice President - Business Development (Age 60)
- Andrea Marie DiFabio, Executive Vice President, Chief Legal Officer (Age 48)
- Diantha Duvall, Vice President - Finance, Chief Accounting Officer (Age 45)
- Alexander J. Denner Ph.D., Independent Director (Age 47)
- Louis J. Paglia, Independent Director (Age 59)
Has Bioverativ been receiving favorable news coverage?
Media coverage about BIVV stock has been trending somewhat negative recently, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Bioverativ earned a media sentiment score of 0.00 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.49 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Bioverativ?
Shares of BIVV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bioverativ's stock price today?
One share of BIVV stock can currently be purchased for approximately $104.98.
How big of a company is Bioverativ?
Bioverativ has a market capitalization of $11.36 billion and generates $1.17 billion in revenue each year. Bioverativ employs 460 workers across the globe.
How can I contact Bioverativ?
Bioverativ's mailing address is 225 2nd Ave, WALTHAM, MA 02451-1122, United States. The biotechnology company can be reached via phone at +1-781-6634400 or via email at [email protected]
MarketBeat Community Rating for Bioverativ (BIVV)
MarketBeat's community ratings are surveys of what our community members think about Bioverativ and other stocks. Vote "Outperform" if you believe BIVV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIVV will underperform the S&P 500 over the long term. You may vote once every thirty days.
